Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Delayed Quote. Delayed  - 10/20 05:30:07 pm
234.4 CHF   -1.76%
10/20 INOVIO PHARMACE : Begins Phase 1b/2 Cancer Efficacy Trial Combining ..
10/19DJEuropean Corporate Roundup for Thursday
10/19DJEuropean Corporate Roundup for Thursday
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
04:03a-$1.07 EPS Expected for Foundation Medicine, Inc. $FMI This Quarter  
02:31aContrasting Alkermes PLC $ALKS and Foundation Medicine $FMI  
01:51aRoche's newer drugs have some heavy lifting to do  
10/21Roche (RHHBY) Reports Sales Numbers for First 9 Months -  
10/20Moloney Securities Asset Management LLC Has $650,000 Holdings in Roche Holdin.. 
10/20Roche Holding Ltd. $RHHBY Stake Increased by Eqis Capital Management Inc.  
10/20Roche Holding given CHF 260 PT by Morgan Stanley. neutral rating.  
10/20Roche Holding given CHF 254 PT by Deutsche Bank AG. neutral rating.  
10/20Roche Holding given CHF 226 PT by Kepler Capital Markets. neutral rating.  
10/20Roche Holding given CHF 203 PT by HSBC Holdings plc. sell rating.  
10/20Wall Street seems to expect too much from Roche's new drugs  
10/20$ROG - Roche Holding Ltd. #ROG Given a CHF 295 Price Target by Jefferies Grou.. 
10/20#TourofGuangxi Correction: it seems it's @nicholasroche in the breakaway, not..
2
10/20Roche may be asking too much of its next generation of medicines  
10/20Wall Street seems to expect too much from Roche's new drugs
15
10/20Roche's newer drugs have some heavy lifting to do
1
10/20Roche feeling first effects of biosimilar Rituxan: Biopharma Dive
1
10/19Wall Street seems to expect too much from Roche's new drugs
5
10/19Wall Street may be expecting too much from Roche's new drugs
2
10/19Wall Street seems to expect too much from Roche's new drugs
4
10/19Roche Holding given CHF 260 PT by UBS AG. neutral rating.  
10/19Roche Holding ADR reports Q3 results  
10/19$RHHBY: Roche Hldg reports Q3 sales and reaffirms FY17 sales outlook  
10/19Roche Q3 top line up 5%, guidance confirmed  
10/19New MS drug #Ocrevus lifts #Roche as #biosimilars bite, with #Rituxan/MabTher..
3
10/19UPDATE 2-New MS drug lifts Roche as biosimilars bite in Europe  
10/19Swiss biotech group Roche sees 5 pct rise in 9-month sales - Washington Post .. 
10/19Same old, same old at #Roche. Since the Novo Nordisk romp my current fav Eur.. 
10/19UPDATE 1-Roche Q3 sales beat forecasts as Ocrevus shines  
10/19Roche third-quarter sales beat forecasts as Ocrevus shines
2
10/19Roche Q3 sales beat forecasts as Ocrevus shines  
10/19US helps offset lower European sales for Roche  
10/19US helps offset lower European sales for Roche  
10/19US helps offset lower European sales for Roche
6
10/19US helps offset lower European sales for Roche  
10/18Senseonics Holdings Inc $SENS Shares Down 8.8%  
10/18Roche Holding Ltd. $RHHBY Downgraded by Citigroup Inc. to Neutral  
10/18Roche Holding downgraded by Citigroup Inc. to neutral.  
10/18I am certainly concerned about price caps: Shravan Subramanyam, MD of Roche D.. 
10/18Steven J. Kafka Sells 3,361 Shares of Foundation Medicine, Inc. $FMI Stock  
10/18Roche Holding given CHF 255 PT by Citigroup Inc.. neutral rating.  
10/18Roche Holding given CHF 325 PT by Goldman Sachs Group, Inc. (The). buy rating.. 
10/17$FMI - Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Foundati.. 
10/17Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMoti.. 
10/17Steven J. Kafka Sells 3,361 Shares of Foundation Medicine, Inc. $FMI Stock  
10/16Senseonics Holdings, Inc. Schedules Third Quarter 2017 Earnings Release and C.. 
10/16#2 today Roche ties a $387M knot with Warp Drive Bio in collaboration spotlig..
5
10/16Big #pharma firm Roche, will pay up to $87 million for access to novel natura..
7
10/16Roche ties a $387M knot with Warp Drive Bio in collaboration spotlighting new.. 
10/16Roche Holding's buy rating reiterated at J P Morgan Chase & Co.  
More tweets
Qtime:223
Financials ( CHF)
Sales 2017 53 411 M
EBIT 2017 18 409 M
Net income 2017 11 152 M
Debt 2017 9 884 M
Yield 2017 3,67%
P/E ratio 2017 17,46
P/E ratio 2018 15,97
EV / Sales 2017 4,00x
EV / Sales 2018 3,78x
Capitalization 204 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 272  CHF
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.5.55%207 116
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
MERCK AND COMPANY7.88%174 223
AMGEN27.41%133 501